Midkine promotes breast cancer cell proliferation and migration by upregulating NR3C1 expression and activating the NF-κB pathway

• DOI: 10.1007/s11033-022-07116-7
• Publication Date: 2022-01-13T17:02:44Z
• Authors: Lin Zhang; Li Song; Yanyan Xu; Yuting Xu; Maojin Zheng; Peng Zhang; Qingling Wang
• Keywords: Midkine; NF-kappa B; Breast Neoplasms; 3. Good health; 03 medical and health sciences; Receptors, Glucocorticoid; 0302 clinical medicine; Cell Movement; Cell Line, Tumor; Humans; Female; Neoplasm Invasiveness; Cell Proliferation; Signal Transduction

Breast cancer (BC) is the most common malignancy in females and is the second leading cause of cancer-related death among women worldwide. Midkine (MDK) is a heparin-binding growth factor that is abnormally expressed at high levels in various human malignancies. We aimed to uncover the biological function and molecular mechanism of MDK in BC cells.MDA-MB-231-shMDK and T47D-shMDK BC cells were established. The in vitro biological functions of MDK were demonstrated by CCK-8 assays, Transwell assays and Western blotting, whereas qPCR pathway arrays were implemented to explore the mechanism of MDK in BC cells. Functionally, we verified that silencing MDK significantly suppressed BC cell proliferation and migration by inhibiting the activation of the nuclear factor kappa B (NF-κB) pathway and the nuclear distribution of NF-κB. Meanwhile, Ingenuity Pathway Analysis (IPA) and a qPCR pathway array revealed that silencing MDK decreased the expression of NR3C1, a potential downstream target of the NF-κB pathway. We also confirmed that treatment with an NF-κB inhibitor suppressed NR3C1 expression in BC cells. Finally, we demonstrated that silencing NR3C1 repressed BC cell proliferation and migration.Our findings highlight a novel mechanism by which MDK influences BC progression via regulation of the NF-κB-NR3C1 pathway.